RIPK3 (receptor interacting serine/threonine kinase 3) is a critical mediator of necroptosis, a form of programmed cell death characterized by cell rupture 1. The protein functions primarily through interaction with RIPK1 via RIP homotypic interaction motifs and phosphorylates mixed lineage kinase domain-like protein (MLKL) at threonine 357 and serine 358 residues, which is essential for necroptosis execution 2. RIPK3 activation occurs through various triggers including TNF, Toll-like receptors, or viral infections when caspase-8 is inhibited 1. Beyond cell death, RIPK3 serves scaffolding functions in inflammatory signaling pathways, promoting cytokine production through K63- and M1-linked ubiquitination independently of necroptosis 3. The protein also acts as a damage-associated molecular pattern when released extracellularly, binding to RAGE receptors and activating CaMKII signaling to exacerbate tissue injury 4. RIPK3 modulates metabolic functions by dampening mitochondrial bioenergetics and affecting lipid droplet dynamics in liver disease 5. Clinically, elevated plasma RIPK3 levels correlate with poor outcomes in acute myocardial infarction patients 4, and RIPK3 deficiency ameliorates various pathological conditions including sepsis and metabolic liver disease, making it a potential therapeutic target 6.